10-Q: Ludwig Enterprises Q1 2026 Financial Results
Quarterly Report
Ludwig Enterprises reported a net income of $218,847 for Q1 2026, driven primarily by non-cash gains rather than operational revenue.
Summary
- Reported net income of $218,847 for the three months ended March 31, 2026, compared to a net loss of $540,943 in the same period of 2025.
- Operating expenses totaled $564,979, primarily driven by sales, marketing, and professional fees.
- The company maintains a significant working capital deficit of $5,037,861.
- Cash on hand as of March 31, 2026, was $18,323.
- The company has not yet generated revenue from operations.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a high-risk situation due to the substantial doubt regarding the company's ability to continue as a going concern, the significant working capital deficit, and the reliance on non-cash gains to report net income.
Positives
- Achieved a net income of $218,847 for the quarter.
- Recognized a $825,000 gain on equity securities exchange and a $175,000 unrealized gain on marketable securities.
- Entered into an exclusive distribution agreement with Canary Oncoceutics, Inc. in May 2026 to expand market reach in India.
Negatives
- Recurring losses from operations and lack of revenue generation.
- Working capital deficit of $5,037,861.
- Management concluded that internal controls over financial reporting were not effective as of March 31, 2026.
- Substantial doubt exists regarding the company's ability to continue as a going concern.
Risks
- Inadequate capital and barriers to raising additional financing.
- Failure to earn revenues or profits.
- Volatility or decline of stock price.
- Potential fluctuation in annual results.
- Insufficient revenues to cover operating costs.
Future Outlook
The company expects revenues from sales of planned products to begin during the second half of 2026. Management plans to raise funds to execute operations, seek strategic acquisitions of health care technology, and explore partnership opportunities, though there is no certainty regarding the success of these plans.
Management Comments
- Management has concluded that substantial doubt exists about the company's ability to continue as a going concern.
- Management expects operating expenses for 2026 to exceed those of 2025, contingent on obtaining capital.
Industry Context
StockSavvy.ai notes that Ludwig Enterprises operates in the highly competitive and capital-intensive health technology sector, specifically focusing on mRNA-based diagnostics. The company's reliance on non-cash gains to achieve profitability is a common characteristic of early-stage biotech firms that have yet to commercialize their intellectual property.
Comparison to Industry Standards
- The company's reliance on convertible debt and warrants is typical for micro-cap biotech companies seeking to bridge funding gaps before commercialization.
- The lack of revenue is consistent with pre-commercial stage diagnostic companies, though the working capital deficit is significantly higher than industry peers with more robust balance sheets.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Evaluation | Management concluded that internal controls over financial reporting were not effective as of March 31, 2026. | 2026-03-31 | Increased risk of material misstatements in financial reporting. |
Legal Proceedings
- None.
Related Party Transactions
- Settlement agreement with former CEO Charles Todd, Jr. involving cash payments and issuance of restricted common stock.
- Ongoing consulting agreements with Thornhill Advisory Group, Inc. and Dr. Marvin S. Hausman.
Stakeholder Impact
- Shareholders face significant dilution risk from potential future capital raises and the conversion of outstanding notes and warrants.
- Creditors are exposed to the company's liquidity challenges and going concern status.
Next Steps
- Continue efforts to raise capital to fund operations.
- Execute the distribution agreement with Canary Oncoceutics, Inc.
- Seek strategic acquisitions of health care technology.
- Explore prospective partnership opportunities.
Key Dates
| Date | Description |
|---|---|
| 2026-02-05 | Issuance of convertible promissory note and warrant to Alumni Capital LP. |
| 2026-02-27 | Exchange of Series B Preferred Stock for Exousia Bio, Inc. common stock. |
| 2026-03-31 | Quarterly period end date. |
| 2026-05-01 | Entered into Exclusive Distribution Agreement with Canary Oncoceutics, Inc. |
| 2026-05-13 | Issuance of convertible promissory note and warrant to QC Funding LLC. |
| 2026-05-29 | Filing date of the Form 10-Q. |
Recommendation
sellThe company's precarious financial position, characterized by a massive working capital deficit, lack of operational revenue, and substantial doubt regarding its ability to continue as a going concern, makes it a high-risk investment unsuitable for most investors.
Keywords
Ludwig Enterprises, mRNA technology, biomarkers, health care technology, diagnostic medical services, SEC filing, 10-Q
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.